Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein–Barr virus infection. A different subtype of AILD-TL?

Lome-Maldonado, Carmen; Canioni, Danielle; Hermine, Olivier; Delabesse, Éric; Damotte, Diane; Raffoux, Emmanuel; Gaulard, Philippe; Macintyre, Elizabeth; Brousse, Nicole

doi:10.1038/sj.leu.2402642

Cited by 42 publications

(34 citation statements)

References 38 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whether these signals indicate clonal B-cell subpopulations that are also described in healthy individuals 34 or represent true crosslineage rearrangements in the malignant T cells cannot be definitely judged by this analysis alone, although cross-lineage Ig rearrangements would rather result in comparable strong clonal PCR products as generated by TCR PCR. Incidence of Ig clonality was highest in AILT (32%), close to the frequencies identified by Smith et al 28 and Lome-Moldonado et al, 35 but higher than reported by Frizzera. 27 In this entity, Ig clonality most likely corresponds to expanded B-cell clones 28,[35][36][37][38] in line with the occurrence of secondary Epstein-Barr viruspositive B-cell lymphoma after AILT.…”

Section: Anaplastic Large Cell Lymphomasupporting

confidence: 53%

“…Incidence of Ig clonality was highest in AILT (32%), close to the frequencies identified by Smith et al 28 and Lome-Moldonado et al, 35 but higher than reported by Frizzera. 27 In this entity, Ig clonality most likely corresponds to expanded B-cell clones 28,[35][36][37][38] in line with the occurrence of secondary Epstein-Barr viruspositive B-cell lymphoma after AILT. 38,39 Also in T-LGL the association with B-cell proliferations is described.…”

Section: Anaplastic Large Cell Lymphomasupporting

confidence: 53%

See 1 more Smart Citation

Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936

White²,

et al. 2006

Self Cite

View full text Add to dashboard Cite

Polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) and immunoglobulin (Ig) gene rearrangements is an important diagnostic tool in mature T-cell neoplasms. However, lack of standardized primers and PCR protocols has hampered comparability of data in previous clonality studies. To obtain reference values for Ig/TCR rearrangement patterns, 19 European laboratories investigated 188 T-cell malignancies belonging to five World Health Organization-defined entities. The TCR/Ig spectrum of each sample was analyzed in duplicate in two different laboratories using the standardized BIOMED-2 PCR multiplex tubes accompanied by international pathology panel review. TCR clonality was detected in 99% (143/145) of all definite cases of T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, peripheral T-cell lymphoma (unspecified) and angioimmunoblastic T-cell lymphoma (AILT), whereas nine of 43 anaplastic large cell lymphomas did not show clonal TCR rearrangements. Combined use of TCRB and TCRG genes revealed two or more clonal signals in 95% of all TCR clonal cases. Ig clonality was mostly restricted to AILT. Our study indicates that the BIOMED-2 multiplex PCR tubes provide a powerful strategy for clonality assessment in T-cell malignancies assisting the firm diagnosis of T-cell neoplasms. The detected TCR gene rearrangements can also be used as PCR targets for monitoring of minimal residual disease.

show abstract

Section: Anaplastic Large Cell Lymphomasupporting

confidence: 53%

Section: Anaplastic Large Cell Lymphomasupporting

confidence: 53%

Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936

White²,

et al. 2006

Self Cite

View full text Add to dashboard Cite

show abstract

“…Lome-Maldonado et al 4 have reported in a series of angioimmunoblastic Tcell lymphoma with a large B-cell proliferation that the presence of the large B cells made no significant prognostic impact. In their particular study, they proposed angioimmunoblastic T-cell lymphoma with a large B-cell proliferation as a specific subtype of angioimmunoblastic T-cell lymphoma, so that it would not be mistaken for a T-cell-rich large B-cell lymphoma.…”

Section: Discussionmentioning

confidence: 99%

“…3 Such a proliferation has also been reported in angioimmunoblastic T-cell lymphoma. 4 Recently, expression of CD10 by the neoplastic T cells in angioimmunoblastic T-cell lymphoma was reported. 5 As cases of peripheral T-cell lymphoma, unspecified, failed to show a similar pattern of aberrant CD10 expression, CD10 emerged as a useful tool to help discriminate peripheral T-cell lymphoma from angioimmunoblastic T-cell lymphoma.…”

mentioning

confidence: 99%

CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells

et al. 2006

View full text Add to dashboard Cite

CD10 expression by the neoplastic T cells in angioimmunoblastic T-cell lymphoma was recently described. As cases of peripheral T-cell lymphoma, unspecified, fail to show similar CD10 expression, this feature helps discriminate between these two entities, particularly in cases exhibiting morphologic overlap. Given these findings, we studied CD10 expression in a subtype of peripheral T-cell lymphoma known as peripheral T-cell lymphoma complicated by a proliferation of large B cells and compared it with angioimmunoblastic T-cell lymphoma and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation. A total of 33 cases were identified including peripheral T-cell lymphoma complicated by a proliferation of large B cells (10), angioimmunoblastic T-cell lymphoma (10) and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation (13). Diagnoses were established by hematoxylin and eosin (H&E) stain, immunohistochemistry and/or molecular findings (polymerase chain reaction for T-cell receptor-gamma gene rearrangement). Two of 10 cases of peripheral T-cell lymphoma complicated by a proliferation of large B cells showed aberrant CD10 expression (20%) compared to 9/10 cases of angioimmunoblastic T-cell lymphoma (90%) and 8/13 of angioimmunoblastic T-cell lymphoma with a large B-cell proliferation (62%). One case each of angioimmunoblastic T-cell lymphoma and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation showed a rare, but not unequivocal, CD10( þ ) atypical cell. Four cases of angioimmunoblastic T-cell lymphoma with a large B-cell proliferation were CD10 negative. Of the 2 CD10( þ ) peripheral T-cell lymphoma complicated by a proliferation of large B cells, one had no H&E or IHC features of angioimmunoblastic T-cell lymphoma and showed only a rare positive cell. The second case, a lung biopsy, exhibited diffuse CD10 tumor cell positivity. The predominant staining pattern in the CD10( þ ) cases was characterized by scattered, mostly individual, morphologically neoplastic cells. A rare case showed clusters of positive cells. Our data indicate that only 20% of cases of peripheral T-cell lymphoma complicated by a proliferation of large B cells show CD10 expression by the neoplastic T cells in contrast to angioimmunoblastic T-cell lymphoma and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation which exhibit CD10 staining in 90 and 62% of cases, respectively. This finding does not reach statistical significance with a P-value of 0.57 (Fisher's exact test). As these entities appear to be biologically distinct and may portend different overall survivals, CD10 expression may serve as an additional discriminating criterion.

show abstract

“…Clinically, the disease is quite aggressive and can be further complicated by possible transformation of the clonal EBV? B-cells into a diffuse large B-cell lymphoma [40][41][42]. At immunophenotyping, neoplastic cells are CD3?, CD4?, and more often lack one of more T-cell associated antigens such as CD5 and CD7 [43].…”

Section: Molecular Pathology Of Alclmentioning

confidence: 99%

Molecular genetics of peripheral T-cell lymphomas

2014

View full text Add to dashboard Cite

Peripheral T-cell lymphomas (PTCL) are rare neoplasms that in most instances respond poorly to conventional chemotherapies. Four varieties-PTCL not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), ALK? anaplastic T-cell lymphoma (ALCL), and ALK-ALCL-account for about 60 % of them. Their classification is difficult because of the wide spectrum of morphologic features and the lack of robust immunohistochemical markers. Thus, high-throughput technologies can importantly contribute to their better understanding. In particular, gene expression profiling has cleared the borders among PTCL/NOS, ALK-ALCL and AITL. In fact, gene signatures have been developed even from formalin-fixed paraffin-embedded tissue samples that definitely distinguish one tumor from the other(s). This has important practical implications: for instance on routine diagnostics PTCL/NOS expressing CD30 can be easily confused with ALK-ALCL, but has a much worse prognosis. Therefore, the clear-cut distinction between the two conditions is pivotal to understand the results of ongoing trials with Brentuximab Vedotin, targeting the CD30 molecule. Besides improving the diagnosis, molecular studies have provided the rationale for the usage of novel drugs in the setting of PTCLs, such as ALK inhibitors in ALK? ALCL, anti-angiogenetic drugs in AITL, and tyrosine kinase inhibitors in PTCL/NOS and ALK? and ALK-ALCLs.

show abstract

Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein–Barr virus infection. A different subtype of AILD-TL?

Cited by 42 publications

References 38 publications

Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936

Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936

CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells

Molecular genetics of peripheral T-cell lymphomas

Contact Info

Product

Resources

About